The Quality Overall Summary (QOS) is an element of a drug marketing application that provides a substantially condensed summary of the quality-related data provided in the submission. Regulators can use the QOS to more effectively assess applications and more rapidly comprehend the quality information in the context of patient risk, including the proposed control strategy and any other planned steps to mitigate that risk. Patients benefit from the greater assessment efficiency by having improved access to drugs that are designed and manufactured to consistently and safely fulfill claims in the label.
News & Trends
Procurar
Recentes
- European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure
- European medicines agencies network strategy to 2028
- MDCG 2024-11 – Guidance on qualification of in vitro diagnostic medical devices (October 2024)
- Study supporting the monitoring of the availability of medical devices on the EU market
- Corrective and preventive action (CAPA) plan assessment: guidance and templates for conformity assessment bodies, notified bodies, designating authorities and joint assessment teams
- Iniciativa para melhorar a eficiência na aprovação de novos medicamentos na UE
- Consulta pública a decorrer para Projeto de Regulamento de Execução sobre consultas científicas conjuntas de medicamentos
- EUDAMED user guide Guidelines on Data Exchange with EUDAMED